Navigation Links
Abbott Announces Positive Nine-Month Results From the World's First,Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent

Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products that are recognized internationally for their safety and effectiveness in treating patients with vascular disease.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.

CONTACT: media, Karin Bauer Aranaz, +1-650-868-2999, or financial, TinaVentura, +1-847-935-9390, both of Abbott

Web site: http://www.abbott.com/

Ticker Symbol: (NYSE:ABT)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3

Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
3. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
4. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
5. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
6. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
7. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
8. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
9. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
10. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:12/1/2008)...e-FirstCall/ -- GeoVax Labs, Inc.,(OTC Bulletin B...y developing,human vaccines for diseases caused b...infectious agents, announced today that the launch...lace in twelve sites across North and South Americ...th The National Institutes of,Health (NIH), and t...
(Date:11/28/2008)...ewswire-FirstCall/ -- Eli Lilly and Company,(NYSE...Application (sNDA) from,the U.S. Food and Drug Ad...),for the management of chronic pain. Lilly plans... 2009, adding data from a recently completed posit...nee. , The decision does not affect duloxet...
(Date:11/25/2008)...ove recovery , , Audio and Web Video Resour...ayo Clinic News Blog. Please see the bottom of thi...Minn., Nov. 25 A Mayo C...n,t think they,re having a stroke -- and as a resu...n worsens. The findings appear in the current issu...
(Date:11/25/2008)... Pharmacyclics, Inc.,(N...as completed a Phase 1,clinical trial with PCI-27...lecule Factor VIIa inhibitor. The trial was conduc...e the safety and pharmacologic effect of,PCI-2748...n a linear dose,response in the International Nor...
Breaking Medicine Technology:GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 2GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Do You Know You're Having a Stroke? 2Do You Know You're Having a Stroke? 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 2Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 4Research Attributes Lack of HIV AIDS Vaccine to Use of Chimpanzees 3225 1Research Attributes Lack of HIV AIDS Vaccine to Use of Chimpanzees 3225 2Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer 5246 1Cold Spring Harbor Laboratory scientists trace a novel way cells are disrupted in cancer 5246 2Surface tension drives segregation within cell mixtures 5244 1Surface tension drives segregation within cell mixtures 5244 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3223 1Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3223 2Ironwood and Collaborators Present Preclinical Data Demonstrating That Cyclic GMP Alleviates Intestinal Pain 3223 3
...ase 1 Colorectal and Prostate Cancer,Trials To Be ...RANCISCO, Calif., May 23, 2007 /PRNewswire-FirstCa...ceutical company,focused on oncology, today announ...the Company,s lead product candidate, in patients,...ed in a poster,session at the 43rd Annual Meeting ...
...07 /PRNewswire-FirstCall/ -- Vical,Incorporated to...study, a DNA vaccine formulated with the company,s...needle-free injection,yielded significantly higher...ne delivered by needle and syringe. In a,separate ...of,unformulated vaccine yielded comparable improve...
Other Medicine Technology:Poniard Pharmaceuticals Announces Clinical Data from Picoplatin,Phase 2 Small Cell Lung Cancer Trial To Be Presented at American,Society of Clinical Oncology Annual Meeting 2Poniard Pharmaceuticals Announces Clinical Data from Picoplatin,Phase 2 Small Cell Lung Cancer Trial To Be Presented at American,Society of Clinical Oncology Annual Meeting 3Poniard Pharmaceuticals Announces Clinical Data from Picoplatin,Phase 2 Small Cell Lung Cancer Trial To Be Presented at American,Society of Clinical Oncology Annual Meeting 4Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues 2Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues 3Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues 4
(Date:12/2/2008)...a leading provider of onsite health services and t...e, the athletic products company, has selected Mar...te health clinics and to provide health services t... Burlington, VT (PRWEB) Decem... of onsite employee health services and technology...
(Date:12/2/2008)...nal Day of Disabled Persons is recognized on Dec. ...g boy born with backwards pointing feet. After fre...ospital docked in Liberia, Benedict,s feet are cor...children his age. High resolution photos and vid...g , Garden Valley, TX (V...
(Date:12/2/2008)...unces that the SouthEast Alaska Regional Health Co...the Rhapsody™ Integration Engine to help the...armacy, laboratory and business programs communica...tivity to statewide systems such as VacTrAK (the S...an MIS and clinical documentation tool used by sub...
(Date:12/2/2008)...orola, Inc. (NYSE: MOT ),announced today that i...enable,three hospitals managed by leading Europea...to deliver voice, data and video services. The inn... broadband infrastructure to support,multimedia s..., eliminating,the need for additional cabling or ...
Breaking Medicine News(10 mins):Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 2Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 3Health News:Mercy Ships Recognizes International Day of Disabled Persons 2Health News:Mercy Ships Recognizes International Day of Disabled Persons 3Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 2Health News:SouthEast Alaska Regional Health Consortium Selects Orion Health's Rhapsody Integration Engine for Full-scale Application Integration and Monitoring 3Health News:Motorola Extends the Delivery of Personalized Media Experiences to Hospital Group Generale De Sante 2Health News:Motorola Extends the Delivery of Personalized Media Experiences to Hospital Group Generale De Sante 3
...al cardiologist at the Washington Hospital Center ...ergy) to restore blood flow in blocked arteries. /...eople suffering from advanced diabetes as it leads...ns such as amputation. People with diabetes and e...
...s of Kryptiq's Care Manager Diabetes Module at the...ems Society (HIMSS) conference. // This module ...nts who benefited. The one year study showed that ...holesterol and blood pressure levels. Providence M...
...y men contact in Hong Kong has been in a way respo... a latest report. // Government health officials ...vember 2005, had HIV with similar gene sequencing,...st reported. The discovery was made when all the ...
...d be as simple as swallowing a spongy pill with a ...ts of Cambridge University researchers // that can... UK every year. It is the ninth most commonly occu...he windpipe, the pill is pulled out, gently scrapi...
Other Medicine News:Health News:Laser Used To Clear Blocked Arteries Preventing Amputation, 2Health News:Kryptiq Care Manager Diabetes Module Effective In Managing Diabetes 2
Gold Labeling kit for antibodies, the Coat-Block-Run Conjugation Kit pH 5-8; contains 1 bottle each of 20 nm and 40 nm Naked Gold
Colloidal Gold Conjugated, Goat anti-mouse IgG (H&L) - 12 OD
Colloidal Gold Conjugated, Goat anti-mouse IgG (H&L) - 50 OD
Colloidal Gold Conjugated, Goat anti-human IgM (Mu Chain) - 12 OD
Medicine Products: